BRIEF published on 03/21/2026 at 10:10, 12 days 4 hours ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 12 days 4 hours ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 2 months 21 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 4 months ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 6 months 6 days ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 6 months 6 days ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 1 year 8 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 1 year 8 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 04/02/2026 at 14:10, 29 minutes ago Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care
Published on 04/02/2026 at 14:00, 39 minutes ago Electrovaya Collaborates on U.S. Department of Energy-Funded Project to Advance Energy Storage for Critical Infrastructure
Published on 04/02/2026 at 13:45, 54 minutes ago Amarc Confirms Boliden's Ongoing Participation at Duke Copper-Gold District and Provides District Update
Published on 04/02/2026 at 13:30, 1 hour 9 minutes ago Revival Gold Consolidates Mercur Gold Project Paving The Way For Redevelopment
Published on 04/02/2026 at 13:15, 1 hour 24 minutes ago F3 Announces Bought Deal Private Placement for Gross Proceeds of C$5 Million
Published on 04/02/2026 at 14:25, 13 minutes ago Tata Communications Maintains a Leader Position for 13th Straight Year in Gartner® Magic Quadrant™
Published on 04/02/2026 at 14:00, 38 minutes ago Diginex Appoints Chief Operating Officer and Chief Administrative Officer to Accelerate Implementation of Business Strategy
Published on 04/02/2026 at 13:50, 48 minutes ago Hautalampi permitting process progressing – supplementary information request received
Published on 04/02/2026 at 13:43, 55 minutes ago Edison issues report on VinaCapital Vietnam Opportunity Fund (VOF)
Published on 04/02/2026 at 13:20, 1 hour 18 minutes ago Phemex Publishes April 2026 Proof of Reserves, Reporting 131% Total Reserve Ratio
Published on 04/02/2026 at 08:30, 6 hours 9 minutes ago Edenred and EnBW partner to simplify electric fleet management in Germany
Published on 04/02/2026 at 08:05, 6 hours 34 minutes ago Neoen announces the launch of France's largest battery
Published on 04/02/2026 at 08:00, 6 hours 39 minutes ago Availability of the preparatory documents for the Annual General Meeting of OPmobility SE
Published on 04/02/2026 at 08:00, 6 hours 39 minutes ago Neoen announces Ako Battery, its first big battery in Japan, during the French President’s official visit
Published on 04/02/2026 at 07:30, 7 hours 9 minutes ago Launch of a €225 million tranche of its share buyback program
